Gladstone Commercial (GOOD) to pay $0.13 on Dec 31, 2019; Endurant Capital Management LP Decreased By $1.60 Million Its Sarepta Therapeutics (SRPT) Stake

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Gladstone Commercial Corp (NASDAQ:GOOD) is expected to pay $0.13 on Dec 31, 2019. (NASDAQ:GOOD) shareholders before Dec 18, 2019 will receive the $0.13 dividend. Gladstone Commercial Corp’s current price of $22.64 translates into 0.55% yield. Gladstone Commercial Corp’s dividend has Dec 19, 2019 as record date. Oct 8, 2019 is the announcement. The stock increased 0.18% or $0.04 during the last trading session, reaching $22.64. About 148,967 shares traded or 21.09% up from the average. Gladstone Commercial Corporation (NASDAQ:GOOD) has risen 9.25% since December 4, 2018 and is uptrending. It has outperformed by 9.25% the S&P500. Some Historical GOOD News: 17/04/2018 – LNG LTD SAYS BUYER OF GLADSTONE LNG IS LNG QUEENSLAND PTY; 12/03/2018 GLADSTONE COMMERCIAL REPORTS $14.3M INDUSTRIAL PURCHASE IN; 01/05/2018 – Gladstone Commercial 1Q FFO 40c/Shr; 10/04/2018 – DoJ MO Western: Former Treasurer Pleads Guilty to Embezzling from Gladstone Firefighters Union; 12/04/2018 – Analysis: Positioning to Benefit within GDS HOLDINGS, California Water Service Group Holding, Gladstone Commercial, Ocean Rig U; 16/04/2018 – LNG SAYS GLADSTONE LNG SALE PACT EXECUTED W/ 3RD-PARTY BUYER; 27/04/2018 – Peapack Gladstone 1Q EPS 57c; 23/04/2018 – DJ Gladstone Commercial Corporation, Inst Holders, 1Q 2018 (GOOD); 01/05/2018 – Gladstone Commercial 1Q EPS 6c; 30/04/2018 – Gladstone Commercial Corporation Earnings Call and Webcast Information

Endurant Capital Management Lp decreased Sarepta Therapeutics Inc (SRPT) stake by 73.87% reported in 2019Q2 SEC filing. Endurant Capital Management Lp sold 10,611 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 28.76%. The Endurant Capital Management Lp holds 3,753 shares with $570,000 value, down from 14,364 last quarter. Sarepta Therapeutics Inc now has $8.30 billion valuation. The stock increased 0.06% or $0.07 during the last trading session, reaching $111.38. About 1.23M shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 29.09% since December 4, 2018 and is uptrending. It has outperformed by 29.09% the S&P500. Some Historical SRPT News: 23/04/2018 – European Medicines Agency Validates Type Il Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3…; 03/05/2018 – SAREPTA 1Q LOSS/SHR 55C, EST. LOSS/SHR 32C; 30/04/2018 – Merck Seeks Approval for Keytruda Combo as First-Line Treatment for Metastatic Nonsquamous NSCLC; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials; 23/04/2018 – European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed; 08/05/2018 – ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA; 30/04/2018 – FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients With Pegzilarginase in Both Monotherapy and KEYTRUDA Combination Trials; 15/03/2018 – Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting; 15/05/2018 – Healthcor Management LP Exits Position in Sarepta

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on February, 26. They expect $-1.81 earnings per share, up 11.71% or $0.24 from last year’s $-2.05 per share. After $-1.70 actual earnings per share reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.47% negative EPS growth.

Endurant Capital Management Lp increased Surgery Partners Inc stake by 248,915 shares to 287,720 valued at $2.34M in 2019Q2. It also upped Zimmer Biomet Hldgs Inc (ZMH) stake by 32,346 shares and now owns 109,632 shares. Oxford Immunotec Global Plc (NASDAQ:OXFD) was raised too.

Since August 12, 2019, it had 5 buys, and 0 selling transactions for $2.99 million activity. On Monday, August 12 Barry Richard bought $159,250 worth of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 1,300 shares. 16,252 shares valued at $2.00M were bought by INGRAM DOUGLAS S on Monday, August 12. The insider BONNEY MICHAEL W bought $173,480. $219,950 worth of stock was bought by BEHRENS M KATHLEEN on Thursday, September 5.

Investors sentiment decreased to 1.06 in Q2 2019. Its down 0.07, from 1.13 in 2019Q1. It turned negative, as 44 investors sold SRPT shares while 84 reduced holdings. 50 funds opened positions while 95 raised stakes. 68.70 million shares or 7.49% less from 74.26 million shares in 2019Q1 were reported. 1.79M were reported by Invesco Ltd. Timessquare Capital Mngmt Ltd Liability has invested 1.47% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 1,400 were reported by Ellington Mgmt Group Inc Ltd Liability Corp. Pinnacle Limited reported 108,641 shares. Earnest Limited Liability Company has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Qvt LP has 0.1% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 3,117 shares. First Advsr Ltd Partnership has 0.25% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 2,054 were reported by Paloma Prtnrs Mngmt. Charles Schwab Investment Mgmt reported 306,409 shares. California Public Employees Retirement Systems accumulated 94,700 shares. Cap Fincl Advisers Limited Com accumulated 15,623 shares or 0.02% of the stock. Parallax Volatility Advisers Limited Partnership holds 0% or 13,168 shares in its portfolio. California State Teachers Retirement Sys reported 0.03% stake. Exane Derivatives reported 2,023 shares. Partner Fund Mgmt LP owns 546,786 shares for 1.58% of their portfolio.

Among 9 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sarepta Therapeutics has $231 highest and $16000 lowest target. $184.40’s average target is 65.56% above currents $111.38 stock price. Sarepta Therapeutics had 15 analyst reports since June 21, 2019 according to SRatingsIntel. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Friday, September 27 by Citigroup. The company was maintained on Friday, November 8 by Credit Suisse. The firm has “Buy” rating by Bank of America given on Tuesday, August 20. The rating was maintained by Janney Capital with “Buy” on Tuesday, August 20. On Tuesday, June 25 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The rating was maintained by Credit Suisse on Tuesday, August 20 with “Outperform”. Citigroup maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Monday, November 18. Citigroup has “Buy” rating and $16700 target. Robert W. Baird maintained it with “Outperform” rating and $18100 target in Tuesday, August 20 report. Piper Jaffray maintained the shares of SRPT in report on Friday, June 21 with “Buy” rating. The firm earned “Overweight” rating on Friday, October 11 by Morgan Stanley.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Finance.Yahoo.com which released: “Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Yahoo Finance” on December 03, 2019, also Nasdaq.com with their article: “SRPT January 2020 Options Begin Trading – Nasdaq” published on November 21, 2019, Nasdaq.com published: “Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal – Nasdaq” on November 15, 2019. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates – Nasdaq” published on November 08, 2019 as well as Bioworld.com‘s news article titled: “Biopharma companies continue their strong momentum in November – BioWorld Online” with publication date: December 03, 2019.

Among 2 analysts covering Gladstone Commercial Corporation (NASDAQ:GOOD), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Gladstone Commercial Corporation has $2500 highest and $24 lowest target. $24.50’s average target is 8.22% above currents $22.64 stock price. Gladstone Commercial Corporation had 6 analyst reports since September 26, 2019 according to SRatingsIntel. On Friday, November 1 the stock rating was maintained by FBR Capital with “Hold”.

Gladstone Commercial Corporation operates as a real estate investment trust in the United States. The company has market cap of $726.25 million. It engages in investing in and owning net leased industrial and commercial real properties, and making long-term industrial and commercial mortgage loans. It has a 22640 P/E ratio. The firm leases its real estate properties to small businesses, as well as to large public companies.

Since June 14, 2019, it had 3 buys, and 0 selling transactions for $32,345 activity. Cutlip Robert G also bought $10,670 worth of Gladstone Commercial Corporation (NASDAQ:GOOD) on Friday, June 14.

More notable recent Gladstone Commercial Corporation (NASDAQ:GOOD) news were published by: Nasdaq.com which released: “Report: Most Americans Have Good Credit. What if You Don’t? – Nasdaq” on December 04, 2019, also Nasdaq.com with their article: “Is LPL Financial (LPLA) A Good Pick for Value Investors? – Nasdaq” published on December 04, 2019, Nasdaq.com published: “Why Changing This Arrangement Could Be Good for Expedia – Nasdaq” on December 04, 2019. More interesting news about Gladstone Commercial Corporation (NASDAQ:GOOD) were released by: Nasdaq.com and their article: “Good News Looks Priced Into Qualcomm Stock – Nasdaq” published on December 02, 2019 as well as Nasdaq.com‘s news article titled: “This is Why Legg Mason (LM) is a Great Dividend Stock – Nasdaq” with publication date: December 04, 2019.

Investors sentiment decreased to 1.56 in 2019 Q2. Its down 0.09, from 1.65 in 2019Q1. It turned negative, as 14 investors sold Gladstone Commercial Corporation shares while 26 reduced holdings. 23 funds opened positions while 43 raised stakes. 18.19 million shares or 10.37% more from 16.48 million shares in 2019Q1 were reported. California-based California State Teachers Retirement Sys has invested 0% in Gladstone Commercial Corporation (NASDAQ:GOOD). Dimensional Fund Advsr L P invested in 0% or 439,893 shares. Citigroup Inc invested in 0% or 9,328 shares. Moreover, Stifel Financial has 0% invested in Gladstone Commercial Corporation (NASDAQ:GOOD). 1 are held by Huntington Bank. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 2,029 shares. Ameriprise Financial reported 16,949 shares. Royal Commercial Bank Of Canada reported 0% of its portfolio in Gladstone Commercial Corporation (NASDAQ:GOOD). Connor Clark Lunn Mngmt Ltd stated it has 34,378 shares. Delphi Mgmt Inc Ma stated it has 19,948 shares or 0.38% of all its holdings. Parametric Port Assocs Ltd Co holds 0% or 117,971 shares. New York State Common Retirement Fund, a New York-based fund reported 30,900 shares. 65,355 were accumulated by Bard Assocs. Gsa Ptnrs Ltd Liability Partnership stated it has 0.09% of its portfolio in Gladstone Commercial Corporation (NASDAQ:GOOD). Cornerstone Advsrs accumulated 0% or 287 shares.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.